Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

ClinicalTrials.gov ID: NCT06771271

Public ClinicalTrials.gov record NCT06771271. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Non-Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination With Ranibizumab Following Intravitreal Administration in Patients With Diabetic or Uveitic Macular Edema

Study identification

NCT ID
NCT06771271
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
85 participants

Conditions and interventions

Interventions

  • RO7200220 Drug
  • Ranibizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2019
Primary completion
Nov 12, 2023
Completion
Nov 12, 2023
Last update posted
Jan 12, 2025

2019 – 2023

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Retina-Vitreous Associates Medical Group Beverly Hills California 90211
California Retina Consultants Oxnard California 93036
Retina Institute of California Medical Group d/b/a Acuity Eye Group Palm Desert California 92260
Byers Eye Insitute at Stanford Palo Alto California 94303
Florida Eye Associates Melbourne Florida 32901
Retina Vitreous Assoc of FL St. Petersburg Florida 33711
Illinois Retina Associates SC Oak Park Illinois 60304
Cumberland Valley Retina PC Hagerstown Maryland 21740
Sierra Eye Associates Reno Nevada 89502
Wake Forest Baptist Medical Center Winston-Salem North Carolina 27157
Cleveland Clinic Foundation Cleveland Ohio 44195
Oregon HSU Portland Oregon 97239
Mid Atlantic Retina Philadelphia Pennsylvania 19107
Retina Res Institute of Texas Abilene Texas 79606
Austin Clinical Research LLC Austin Texas 78750
Valley Retina Institute P.A. McAllen Texas 78503
Medical Center Ophthalmology Associates San Antonio Texas 78240
Univ of Virginia Ophthalmology Charlottesville Virginia 22903
Karalis Johnson Retina Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06771271, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06771271 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →